|
1
|
Gatenby RA, Silva AS, Gillies RJ and
Frieden BR: Adaptive therapy. Cancer Res. 69:4894–4903. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahmed KM and Li JJ: NF-kappa B-mediated
adaptive resistance to ionizing radiation. Free Radic Biol Med.
44:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roos WP, Thomas AD and Kaina B: DNA damage
and the balance between survival and death in cancer biology. Nat
Rev Cancer. 16:20–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duffy MJ, Maguire TM, McDermott EW and
O'Higgins N: Urokinase plasminogen activator: A prognostic marker
in multiple types of cancer. J Surg Oncol. 71:130–135. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonias SL and Hu J: Urokinase receptor and
resistance to targeted anticancer agents. Front Pharmacol.
6:1542015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mahmood N, Mihalcioiu C and Rabbani SA:
Multifaceted role of the urokinase-type plasminogen activator (uPA)
and its receptor (uPAR): Diagnostic, prognostic, and therapeutic
applications. Front Oncol. 8:242018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ulisse S, Baldini E, Sorrenti S and
D'Armiento M: The urokinase plasminogen activator system: A target
for anti-cancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watabe T, Yoshida K, Shindoh M, Kaya M,
Fujikawa K, Sato H, Seiki M, Ishii S and Fujinaga K: The Ets-1 and
Ets-2 transcription factors activate the promoters for
invasion-associated urokinase and collagenase genes in response to
epidermal growth factor. Int J Cancer. 77:128–137. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lund IK, Nielsen BS, Almholt K, Rono B,
Hald A, Illemann M, Green KA, Christensen IJ, Romer J and Lund LR:
Concomitant lack of MMP9 and uPA disturbs physiological tissue
remodeling. Dev Biol. 358:56–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Wei P, Peng Z, Huang C, Tang H, Jia
Z, Cui J, Le X, Huang S and Xie K: The critical role of
dysregulated FOXM1-PLAUR signaling in human colon cancer
progression and metastasis. Clin Cancer Res. 19:62–72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blasi F and Sidenius N: The urokinase
receptor: Focused cell surface proteolysis, cell adhesion and
signaling. FEBS Lett. 584:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kugaevskaya EV, Gureeva TA, Timoshenko OS
and Solovyeva NI: The urokinase-type plasminogen activator system
and its role in tumor progression. Biomed Khim. 64:472–486. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Su SC, Lin CW, Yang WE, Fan WL and Yang
SF: The urokinase-type plasminogen activator (uPA) system as a
biomarker and therapeutic target in human malignancies. Expert Opin
Ther Targets. 20:551–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harbeck N, Schmitt M, Meisner C, Friedel
C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, et al:
Ten-year analysis of the prospective multicentre Chemo-N0 trial
validates American society of clinical oncology (ASCO)-recommended
biomarkers uPA and PAI-1 for therapy decision making in
node-negative breast cancer patients. Eur J Cancer. 49:1825–1835.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Small W Jr, Bacon MA, Bajaj A, Chuang LT,
Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR,
Viswanathan AN and Gaffney DK: Cervical cancer: A global health
crisis. Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machalek DA, Roberts JM, Garland SM,
Thurloe J, Richards A, Chambers I, Sivertsen T and Farnsworth A:
Routine cervical screening by primary HPV testing: Early findings
in the renewed National cervical screening program. Med J Aust.
211:113–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Au Yeung CL, Tsang TY, Yau PL and Kwok TT:
Human papillomavirus type 16 E6 induces cervical cancer cell
migration through the p53/microRNA-23b/urokinase-type plasminogen
activator pathway. Oncogene. 30:2401–2410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi H, Fujishiro S and Terao T:
Impact of urokinase-type plasminogen activator and its inhibitor
type 1 on prognosis in cervical cancer of the uterus. Cancer Res.
54:6539–6548. 1994.PubMed/NCBI
|
|
20
|
Sugimura M, Kobayashi H, Kanayama N and
Terao T: Clinical significance of urokinase-type plasminogen
activator (uPA) in invasive cervical cancer of the uterus. Gynecol
Oncol. 46:330–336. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY,
Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis,
cancer stem cell phenotype, and oncogenic metabolism in cancer
cells by ionizing radiation. Mol Cancer. 16:102017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kargiotis O, Chetty C, Gogineni V, Gondi
CS, Pulukuri SM, Kyritsis AP, Gujrati M, Klopfenstein JD, Dinh DH
and Rao JS: uPA/uPAR downregulation inhibits radiation-induced
migration, invasion and angiogenesis in IOMM-Lee meningioma cells
and decreases tumor growth in vivo. Int J Oncol. 33:937–947.
2008.PubMed/NCBI
|
|
24
|
Nakada M, Yamashita J, Okada Y and Sato H:
Ets-1 positively regulates expression of urokinase-type plasminogen
activator (uPA) and invasiveness of astrocytic tumors. J
Neuropathol Exp Neurol. 58:329–334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu M, Yu J, Liu H, Ren Y, Ma C, Bu X and
Lan Q: The candidate tumor suppressor gene SLC8A2 inhibits
invasion, angiogenesis and growth of glioblastoma. Mol Cells.
40:761–772. 2017.PubMed/NCBI
|
|
26
|
Reuning U, Wilhelm O, Nishiguchi T,
Guerrini L, Blasi F, Graeff H and Schmitt M: Inhibition of NF-kappa
B-Rel A expression by antisense oligodeoxynucleotides suppresses
synthesis of urokinase-type plasminogen activator (uPA) but not its
inhibitor PAI-1. Nucleic Acids Res. 23:3887–3893. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mesher D, Cuschieri K, Hibbitts S, Jamison
J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A
and Soldan K: Type-specific HPV prevalence in invasive cervical
cancer in the UK prior to national HPV immunisation programme:
Baseline for monitoring the effects of immunisation. J Clin Pathol.
68:135–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pang RT, Leung CO, Ye TM, Liu W, Chiu PC,
Lam KK, Lee KF and Yeung WS: MicroRNA-34a suppresses invasion
through downregulation of Notch1 and Jagged1 in cervical carcinoma
and choriocarcinoma cells. Carcinogenesis. 31:1037–1044. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Wang HK, McCoy JP, Banerjee NS,
Rader JS, Broker TR, Meyers C, Chow LT and Zheng ZM: Oncogenic HPV
infection interrupts the expression of tumor-suppressive miR-34a
through viral oncoprotein E6. RNA. 15:637–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lacombe J and Zenhausern F: Emergence of
miR-34a in radiation therapy. Crit Rev Oncol Hematol. 109:69–78.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li B, Sun M, Gao F, Liu W, Yang Y, Liu H,
Cheng Y, Liu C and Cai J: Up-regulated expression of miR-23a/b
targeted the pro-apoptotic Fas in radiation-induced thymic
lymphoma. Cell Physiol Biochem. 32:1729–1740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harima Y, Sawada S, Nagata K, Sougawa M
and Ohnishi T: Human papilloma virus (HPV) DNA associated with
prognosis of cervical cancer after radiotherapy. Int J Radiat Oncol
Biol Phys. 52:1345–1351. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Datta NR, Kumar P, Singh S, Gupta D,
Srivastava A and Dhole TN: Does pretreatment human papillomavirus
(HPV) titers predict radiation response and survival outcomes in
cancer cervix?-A pilot study. Gynecol Oncol. 103:100–105. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gottgens EL, Ostheimer C, Span PN, Bussink
J and Hammond EM: HPV, hypoxia and radiation response in head and
neck cancer. Br J Radiol. 92:201800472019.PubMed/NCBI
|
|
35
|
Nagel R, Martens-de Kemp SR, Buijze M,
Jacobs G, Braakhuis BJ and Brakenhoff RH: Treatment response of
HPV-positive and HPV-negative head and neck squamous cell carcinoma
cell lines. Oral Oncol. 49:560–566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rieckmann T, Tribius S, Grob TJ, Meyer F,
Busch CJ, Petersen C, Dikomey E and Kriegs M: HNSCC cell lines
positive for HPV and p16 possess higher cellular radiosensitivity
due to an impaired DSB repair capacity. Radiother Oncol.
107:242–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alfano D, Votta G, Schulze A, Downward J,
Caputi M, Stoppelli MP and Iaccarino I: Modulation of cellular
migration and survival by c-Myc through the downregulation of
urokinase (uPA) and uPA receptor. Mol Cell Biol. 30:1838–1851.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sawey MJ, Hood AT, Burns FJ and Garte SJ:
Activation of c-myc and c-K-ras oncogenes in primary rat tumors
induced by ionizing radiation. Mol Cell Biol. 7:932–935. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Horn LC, Pippig S, Raptis G, Fischer U,
Kohler U, Hentschel B and Martin R: Clinical relevance of
urokinase-type plasminogen activator and its inhibitor type 1
(PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z
J Obstet Gynaecol. 42:383–386. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jo M, Eastman BM, Webb DL, Stoletov K,
Klemke R and Gonias SL: Cell signaling by urokinase-type
plasminogen activator receptor induces stem cell-like properties in
breast cancer cells. Cancer Res. 70:8948–8958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Madunic J: The urokinase plasminogen
activator system in human cancers: An overview of its prognostic
and predictive role. Thromb Haemost. 118:2020–2036. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gupta R, Chetty C, Bhoopathi P, Lakka S,
Mohanam S, Rao JS and Dinh DE: Downregulation of uPA/uPAR inhibits
intermittent hypoxia-induced epithelial-mesenchymal transition
(EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol.
38:733–744. 2011.PubMed/NCBI
|
|
43
|
Santibanez JF, Obradovic H, Kukolj T and
Krstic J: Transforming growth factor-β, matrix metalloproteinases,
and urokinase-type plasminogen activator interaction in the cancer
epithelial to mesenchymal transition. Dev Dyn. 247:382–395. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gilder AS, Natali L, Van Dyk DM, Zalfa C,
Banki MA, Pizzo DP, Wang H, Klemke RL, Mantuano E and Gonias SL:
The urokinase receptor induces a mesenchymal gene expression
signature in glioblastoma cells and promotes tumor cell survival in
Neurospheres. Sci Rep. 8:29822018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Narayanaswamy PB, Tkachuk S, Haller H,
Dumler I and Kiyan Y: CHK1 and RAD51 activation after DNA damage is
regulated via urokinase receptor/TLR4 signaling. Cell Death Dis.
7:e23832016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang K, Xing ZH, Jiang QW, Yang Y, Huang
JR, Yuan ML, Wei MN, Li Y, Wang ST, Liu K and Shi Z: Targeting uPAR
by CRISPR/Cas9 system attenuates cancer malignancy and multidrug
resistance. Front Oncol. 9:802019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jing J, Zheng S, Han C, Du L, Guo Y and
Wang P: Evaluating the value of uPAR of serum and tissue on
patients with cervical cancer. J Clin Lab Anal. 26:16–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Duffy MJ and Duggan C: The urokinase
plasminogen activator system: A rich source of tumour markers for
the individualised management of patients with cancer. Clin
Biochem. 37:541–548. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang L, Yang R, Zhao L, Zhang X, Xu T and
Cui M: Basing on uPAR-binding fragment to design chimeric antigen
receptors triggers antitumor efficacy against uPAR expressing
ovarian cancer cells. Biomed Pharmacother. 117:1091732019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pavon MA, Arroyo-Solera I, Cespedes MV,
Casanova I, Leon X and Mangues R: uPA/uPAR and SERPINE1 in head and
neck cancer: Role in tumor resistance, metastasis, prognosis and
therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang P, Ma M and Zhang S: EGF-induced
urokinase plasminogen activator receptor promotes epithelial to
mesenchymal transition in human gastric cancer cells. Oncol Rep.
38:2325–2334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Manzoni C, Kia DA, Vandrovcova J, Hardy J,
Wood NW, Lewis PA and Ferrari R: Genome, transcriptome and
proteome: The rise of omics data and their integration in
biomedical sciences. Brief Bioinform. 19:286–302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yoshimoto Y, Sasaki Y, Murata K, Noda SE,
Miyasaka Y, Hamamoto J, Furuya M, Hirato J, Suzuki Y, Ohno T, et
al: Mutation profiling of uterine cervical cancer patients treated
with definitive radiotherapy. Gynecol Oncol. 159:546–553. 2020.
View Article : Google Scholar : PubMed/NCBI
|
